Clinical characteristics, treatment and outcome of subacute cutaneous lupus erythematosus induced by PD-1/PD-L1 inhibitors.
Humans
Lupus Erythematosus, Cutaneous
/ drug therapy
Female
Middle Aged
Male
Aged
Immune Checkpoint Inhibitors
/ adverse effects
Adult
Aged, 80 and over
Retrospective Studies
Antibodies, Monoclonal, Humanized
/ adverse effects
Nivolumab
/ adverse effects
B7-H1 Antigen
/ antagonists & inhibitors
Treatment Outcome
Programmed Cell Death 1 Receptor
/ antagonists & inhibitors
Antibodies, Antinuclear
/ blood
Skin
/ pathology
Hydroxychloroquine
/ therapeutic use
Biopsy
Drug reaction
Immune-related adverse events
PD-1 inhibitor
Subacute cutaneous lupus erythematosus
Journal
Archives of dermatological research
ISSN: 1432-069X
Titre abrégé: Arch Dermatol Res
Pays: Germany
ID NLM: 8000462
Informations de publication
Date de publication:
26 Oct 2024
26 Oct 2024
Historique:
received:
08
09
2024
accepted:
17
10
2024
revised:
11
10
2024
medline:
26
10
2024
pubmed:
26
10
2024
entrez:
26
10
2024
Statut:
epublish
Résumé
PD-1/PD-L1 inhibitors have increasingly been associated with the occurrence of subacute cutaneous lupus erythematosus (SCLE), but the clinical characteristics and outcomes remain under-explored. Literature on PD-1/PD-L1 inhibitors induced SCLE was retrieved from Chinese and English databases until June 31, 2024, and clinical data of patients were extracted for retrospective analysis. Twenty-nine patients participated, with a median age of 63 years (range 43, 80). The most frequently reported drugs were Nivolumab (51.7%) and pembrolizumab (31.0%). The median time from treatment initiation to SCLE onset was 3 months (range 0.5, 47). Cutaneous manifestations presented primarily as papulosquamous lesions (65.5%) and erythema annulare (31.0%), predominantly occurring on the trunk (51.7%) and arms (51.7%). Serological analysis revealed positive anti-Ro antibodies in 91.7% of patients, positive antinuclear antibodies in 75.0%, and positive anti-La antibodies in 50.0%. Skin biopsies showed interface dermatitis in 65.5% of cases and lymphocyte infiltration in 82.8%. Treatment with topical corticosteroids, systemic corticosteroids, and hydroxychloroquine led to gradual improvement or resolution of the rash, with a median recovery time of 1 month (range 0.5, 11). As the use of PD-1/PD-L1 inhibitors in oncology increases, SCLE should be recognized as a rare cutaneous adverse effect. Histological and serological evaluations play a critical role in diagnosing SCLE. Typically, SCLE resolves on its own with appropriate local and systemic treatment.
Identifiants
pubmed: 39460790
doi: 10.1007/s00403-024-03484-1
pii: 10.1007/s00403-024-03484-1
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
pembrolizumab
DPT0O3T46P
Antibodies, Monoclonal, Humanized
0
Nivolumab
31YO63LBSN
PDCD1 protein, human
0
B7-H1 Antigen
0
CD274 protein, human
0
Programmed Cell Death 1 Receptor
0
Antibodies, Antinuclear
0
Hydroxychloroquine
4QWG6N8QKH
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
722Subventions
Organisme : Natural Science Foundation of Hunan Province
ID : 2023JJ30847
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Jin HT, Ahmed R, Okazaki T (2011) Role of PD-1 in regulating T-cell immunity. Curr Top Microbiol Immunol 350:17–37. https://doi.org/10.1007/82_2010_116
doi: 10.1007/82_2010_116
pubmed: 21061197
Ribas A, Wolchok JD (2018) Cancer immunotherapy using checkpoint blockade. Science 359(6382):1350–1355. https://doi.org/10.1126/science.aar4060
doi: 10.1126/science.aar4060
pubmed: 29567705
pmcid: 7391259
Kong X, Lu P, Liu C, Guo Y, Yang Y, Peng Y, Wang F, Bo Z, Dou X, Shi H, Meng J (2021) A combination of PD-1/PDL1 inhibitors: the prospect of overcoming the weakness of tumor immunotherapy (review). Mol Med Rep 23(5):362. https://doi.org/10.3892/mmr.2021.12001
doi: 10.3892/mmr.2021.12001
pubmed: 33760188
pmcid: 7985997
Ciccarese C, Alfieri S, Santoni M, Santini D, Brunelli M, Bergamini C et al (2016) New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors. Expert Opin Drug Metab Toxicol 12(1):57–75. https://doi.org/10.1517/17425255.2016.1120287
doi: 10.1517/17425255.2016.1120287
pubmed: 26565919
Hassel JC, Heinzerling L, Aberle J, Bähr O, Eigentler TK, Grimm MO et al (2017) Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): evaluation and management of adverse drug reactions. Cancer Treat Rev 57:36–49. https://doi.org/10.1016/j.ctrv.2017.05.003
doi: 10.1016/j.ctrv.2017.05.003
pubmed: 28550712
Hwang SJ, Carlos G, Wakade D, Byth K, Kong BY, Chou S et al (2016) Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort. J Am Acad Dermatol 74(3):455–61e. https://doi.org/10.1016/j.jaad.2015.10.029
doi: 10.1016/j.jaad.2015.10.029
pubmed: 26793994
Curry JL, Tetzlaff MT, Nagarajan P, Drucker C, Diab A, Hymes SR et al (2017) Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. J Cutan Pathol 44(2):158–176. https://doi.org/10.1111/cup.12858
doi: 10.1111/cup.12858
pubmed: 27859479
Shi VJ, Rodic N, Gettinger S, Leventhal JS, Neckman JP, Girardi M et al (2016) Clinical and histologic features of Lichenoid Mucocutaneous eruptions due to Anti-programmed Cell Death 1 and anti-programmed cell death Ligand 1 immunotherapy. JAMA Dermatol 152(10):1128–1136. https://doi.org/10.1001/jamadermatol.2016.2226
doi: 10.1001/jamadermatol.2016.2226
pubmed: 27411054
pmcid: 6108080
Le Naour S, Peuvrel L, Saint-Jean M, Dreno B, Quereux G (2018) Three new cases of bullous pemphigoid during anti-PD-1 antibody therapy. J Eur Acad Dermatol Venereol 32(3):e104–e106. https://doi.org/10.1111/jdv.14579
doi: 10.1111/jdv.14579
pubmed: 28865162
Zarbo A, Belum VR, Sibaud V, Oudard S, Postow MA, Hsieh JJ et al (2017) Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors. Br J Dermatol 176(6):1649–1652. https://doi.org/10.1111/bjd.15237
doi: 10.1111/bjd.15237
pubmed: 27943234
pmcid: 5459625
He Y, Sawalha AH (2018) Drug-induced lupus erythematosus: an update on drugs and mechanisms. Curr Opin Rheumatol 30(5):490–497. https://doi.org/10.1097/BOR.0000000000000522
doi: 10.1097/BOR.0000000000000522
pubmed: 29870500
pmcid: 7299070
Lowe GC, Henderson CL, Grau RH, Hansen CB, Sontheimer RD (2011) A systematic review of drug-induced subacute cutaneous lupus erythematosus. Br J Dermatol 164(3):465–472. https://doi.org/10.1111/j.1365-2133.2010.10110.x9
doi: 10.1111/j.1365-2133.2010.10110.x9
pubmed: 21039412
Bui AN, Singer S, Hirner J, Cunningham-Bussel AC, Larocca C, Merola JF et al (2021) De novo cutaneous connective tissue disease temporally associated with immune checkpoint inhibitor therapy: a retrospective analysis. J Am Acad Dermatol 84(3):864–869. https://doi.org/10.1016/j.jaad.2020.10.054
doi: 10.1016/j.jaad.2020.10.054
pubmed: 33323344
Marzano AV, Lazzari R, Polloni I, Crosti C, Fabbri P, Cugno M (2011) Drug-induced subacute cutaneous lupus erythematosus: evidence for differences from its idiopathic counterpart. Br J Dermatol 165(2):335–341. https://doi.org/10.1111/j.1365-2133.2011.10397.x
doi: 10.1111/j.1365-2133.2011.10397.x
pubmed: 21564069
Ho C, Shumack SP, Morris D (2001) Subacute cutaneous lupus erythematosus associated with hepatocellular carcinoma. Australas J Dermatol 42(2):110–113. https://doi.org/10.1046/j.1440-0960.2001.00491.x
doi: 10.1046/j.1440-0960.2001.00491.x
pubmed: 11309033
Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH et al (2014) Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 32(10):1020–1030. https://doi.org/10.1200/JCO.2013.53.0105
doi: 10.1200/JCO.2013.53.0105
pubmed: 24590637
pmcid: 4811023
Marzano AV, Vezzoli P, Crosti C (2009) Drug-induced lupus: an update on its dermatologic aspects. Lupus 18(11):935–940. https://doi.org/10.1177/0961203309106176
doi: 10.1177/0961203309106176
pubmed: 19762393
Eastham AB, Vleugels RA (2014) Cutaneous lupus erythematosus. JAMA Dermatol 150(3):344. https://doi.org/10.1001/jamadermatol.2013.10393
doi: 10.1001/jamadermatol.2013.10393
pubmed: 24623331
Pratumchart N, Chanprapaph K, Topibulpong N, Tankunakorn J (2022) Subacute Cutaneous Lupus Erythematosus-Like Eruption Induced by Durvalumab: a Case Report and Literature Review. Clin Cosmet Investig Dermatol 13:15:51–62. https://doi.org/10.2147/CCID.S344445
doi: 10.2147/CCID.S344445
Baima B, Sticherling M (2001) Apoptosis in different cutaneous manifestations of lupus erythematosus. Br J Dermatol 144(5):958–966. https://doi.org/10.1046/j.1365-2133.2001.04182.x
doi: 10.1046/j.1365-2133.2001.04182.x
pubmed: 11359381
Marano AL, Clarke JM, Morse MA, Shah A, Barrow W, Selim MA et al (2018) Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy. Br J Dermatol 181(3):580–583. https://doi.org/10.1111/bjd.17245
doi: 10.1111/bjd.17245
pubmed: 30244487
Lin JH, Dutz JP, Sontheimer RD, Werth VP (2007) Pathophysiology of cutaneous lupus erythematosus. Clin Rev Allergy Immunol 33(1–2):85–106. https://doi.org/10.1007/s12016-007-0031-x12
doi: 10.1007/s12016-007-0031-x12
pubmed: 18094949
Shi VJ, Rodic N, Gettinger S, Leventhal JS, Neckman JP, Girardi M et al (2016) Clinical and histologic features of lichenoid mucocutaneous eruptions due to anti-programmed cell death 1 and anti-programmed cell death ligand 1 immunotherapy. JAMA Dermatol 152(10):1128–1136. https://doi.org/10.1001/jamadermatol.2016.222613
doi: 10.1001/jamadermatol.2016.222613
pubmed: 27411054
pmcid: 6108080
Vanderlugt CL, Miller SD (2002) Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol 2(2):85–95. https://doi.org/10.1038/nri72414
doi: 10.1038/nri72414
pubmed: 11910899
Chanprapaph K, Limtong P, Ngamjanyaporn P, Suchonwanit P (2021) Trichoscopic signs in dermatomyositis, systemic lupus erythematosus, and systemic sclerosis: a comparative study of 150 patients. Dermatology 1–11. https://doi.org/10.1159/00052029715
HHasan Ali O, Bomze D, Ring SS, Berner F, Fässler M, Diem S et al (2020) BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors. J Am Acad Dermatol 82(4):854–861. https://doi.org/10.1016/j.jaad.2019.08.04518
doi: 10.1016/j.jaad.2019.08.04518
Osorio JC, Ni A, Chaft JE, Pollina R, Kasler MK, Stephens D et al (2017) Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann Oncol 28(3):583–589. https://doi.org/10.1093/annonc/mdw64020"
doi: 10.1093/annonc/mdw64020
pubmed: 27998967
Gotot J, Gottschalk C, Leopold S, Knolle PA, Yagita H, Kurts C et al (2012) Regulatory T cells use programmed death 1 ligands to directly suppress autoreactive B cells in vivo. Proc Natl Acad Sci U S A 109(26):10468–10473. https://doi.org/10.1073/pnas.1201131109
doi: 10.1073/pnas.1201131109
pubmed: 22689978
pmcid: 3387068
Prokunina L, Gunnarsson I, Sturfelt G, Truedsson L, Seligman VA, Olson JL et al (2004) The systemic lupus erythematosus-associated PDCD1 polymorphism PD1.3A in lupus nephritis. Arthritis Rheum 50(1):327–328. https://doi.org/10.1002/art.11442
doi: 10.1002/art.11442
pubmed: 14730631
Chang J, Werth VP (2016) Therapeutic options for cutaneous lupus erythematosus: recent advances and future prospects. Expert Rev Clin Immunol 12(10):1109–1121. https://doi.org/10.1080/1744666X.2016.1188006
doi: 10.1080/1744666X.2016.1188006
pubmed: 27249209
pmcid: 5843480
Geisler AN, Phillips GS, Barrios DM, Wu J, Leung DYM, Moy AP et al (2020) Immune checkpoint inhibitor-related dermatologic adverse events. J Am Acad Dermatol 83(5):1255–1268. https://doi.org/10.1016/j.jaad.2020.03.1324
doi: 10.1016/j.jaad.2020.03.1324
pubmed: 32454097
pmcid: 7572894
Chasset F, Bouaziz JD, Costedoat-Chalumeau N, Francès C, Arnaud L (2017) Efficacy and comparison of antimalarials in cutaneous lupus erythematosus subtypes: a systematic review and meta-analysis. Br J Dermatol 177(1):188–196. https://doi.org/10.1111/bjd.1531224
doi: 10.1111/bjd.1531224
pubmed: 28112801
Bui AN, Hirner J, Singer SB, Eberly-Puleo A, Larocca C, Lian CG, LeBoeuf NR (2021) De novo subacute cutaneous lupus erythematosus-like eruptions in the setting of programmed death-1 or programmed death ligand-1 inhibitor therapy: clinicopathological correlation. Clin Exp Dermatol 46(2):328–337. https://doi.org/10.1111/ced.14449
doi: 10.1111/ced.14449
pubmed: 32939795
Michot JM, Fusellier M, Champiat S, Velter C, Baldini C, Voisin AL et al (2019) Drug-induced lupus erythematosus following immunotherapy with anti-programmed death-(ligand) 1. Ann Rheum Dis 78(7):e67. https://doi.org/10.1136/annrheumdis-2018-213677
doi: 10.1136/annrheumdis-2018-213677
pubmed: 29858173